AstraZeneca may have published outdated and incomplete data on vaccine tests. Bloomberg reports this with reference to the American Independent Data Monitoring and Security Council.
The AstraZeneca Vaccine Evidence Review Panel reportedly raised concerns with the US Department of Health's National Institute of Allergy and Infectious Diseases, pointing out that AstraZeneca "may have provided an incomplete review of the efficacy data" and the published clinical trial data included "outdated information."
Earlier AstraZeneca reported that clinical trials of the vaccine in the United States, Peru, and Chile showed that the drug completely prevents severe forms of Covid-19 disease, and also protects 79% from a disease accompanied by symptoms.
The company also noted that an independent panel of experts "found no cause for concern with the vaccine." According to it, experts have not identified "an increased risk of thrombosis or cases associated with thrombosis."
Earlier, due to the formation of blood clots in the blood vessels of some vaccinated people, several EU countries have suspended the use of the AstraZeneca vaccine. These are Denmark, Austria, Estonia, Lithuania, Luxembourg, Latvia, and Cyprus. Norway, which is not a member of the EU, has also suspended the use of the vaccine. In addition, in Norway, three doctors were hospitalized with blood clots. Also, vaccination with the AstraZeneca drug was suspended in Bulgaria, Thailand, Romania, Germany, France, and Italy, and in Croatia, where after being vaccinated with the AstraZeneca vaccine, a woman died.
At the same time, it was reported on March 22 that confidence in the coronavirus vaccine from the British-Swedish pharmaceutical concern AstraZeneca had dropped in several European countries at once. In Germany, France, Spain, Italy, most residents consider the drug dangerous.
But later, the European Medicines Agency approved further vaccination against coronavirus with the drug AstraZeneca, since the regulator did not identify the possibility of an increase in the risk of thrombosis from the vaccine.
To date, 17 million people in the EU and the UK have received its Covid-19 vaccine, according to AstraZeneca.